Press Releases

September 26, 2019 at 8:00 AM EDT

Summary Toggle Arcturus Therapeutics Announces $9.8 Million Registered Direct Offering of Common Stock

SAN DIEGO , Sept. 26, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (“Arcturus” or the “Company”), a leading RNA medicines company focused on the discovery, development and commercialization of mRNA therapeutics for rare diseases, today announced that it has entered into definitive agreements with

PDF Version
September 23, 2019 at 8:00 AM EDT

Summary Toggle Arcturus Therapeutics Announces Appointment of Dr. Edward Holmes M.D. and Re-Appointment of Andy Sassine to the Board of Directors

SAN DIEGO , Sept. 23, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (“ Arcturus Therapeutics”) (NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that Professor

PDF Version
August 26, 2019 at 8:00 AM EDT

Summary Toggle Arcturus Therapeutics To Present at Two Investor Conferences in September

SAN DIEGO , Aug. 26, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (“ Arcturus Therapeutics”) (NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that Joseph Payne ,

PDF Version
August 15, 2019 at 8:00 AM EDT

Summary Toggle Arcturus Therapeutics Announces Second Quarter Financial Results and Provides a Corporate Update

Ultragenyx Pharmaceutical, Inc. expands collaboration, becoming Arcturus’ largest shareholder Cystic Fibrosis Foundation increases commitment to $15 million Arcturus receives Orphan Drug Designation from the U.S. FDA for ARCT-810 Conference call and audio webcast at 4:30 PM ET today SAN DIEGO ,

PDF Version
August 7, 2019 at 7:00 AM EDT

Summary Toggle Arcturus to Report Corporate Overview and Financial Results on August 15

SAN DIEGO , Aug. 07, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (NASDAQ: ARCT) (the “Company”), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that it will provide a corporate overview and

PDF Version
August 2, 2019 at 2:00 PM EDT

Summary Toggle Arcturus Therapeutics Announces $2.3 Million Additional Registered Direct Offering of Common Stock

SAN DIEGO , Aug. 02, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (“Arcturus” or the “Company”), a leading RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that it has entered into a definitive agreement with an

PDF Version
August 1, 2019 at 12:30 PM EDT

Summary Toggle Arcturus Therapeutics Announces $10.9 Million Registered Direct Offering of Common Stock

SAN DIEGO , Aug. 01, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (“Arcturus” or the “Company”), a leading RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that it has entered into definitive agreements with

PDF Version
August 1, 2019 at 12:10 PM EDT

Summary Toggle Arcturus Therapeutics Receives up to $15 Million Commitment from the Cystic Fibrosis Foundation to Create mRNA Therapies to Treat Cystic Fibrosis Patients

SAN DIEGO , Aug. 01, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (“Arcturus” or the “Company”), a leading RNA medicines company, today announced that the Cystic Fibrosis Foundation ( CF Foundation ), has increased its commitment to $15 million in conjunction with an amended agreement to advance

PDF Version
July 10, 2019 at 9:00 AM EDT

Summary Toggle Arcturus Therapeutics to Participate in Two Panels at the ROTH RNA Revolution Conference

SAN DIEGO, Calif. , July 10, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (NASDAQ: ARCT) (the “Company”), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that Joseph Payne , President and

PDF Version
June 27, 2019 at 4:01 PM EDT

Summary Toggle Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-810, for Treatment of Ornithine Transcarbamylase (OTC) Deficiency

SAN DIEGO , June 27, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics towards rare, liver and respiratory diseases with significant unmet medical need, today announced the

PDF Version